A competitor service just dumped Salesforce from its stock picks, calling the position a flop and moving on. I understand the reflex. The stock is down roughly 30% in 2026, and the headline growth rate is a shadow of the 20%+ run that built this name over the last decade. But the operating business did not collapse. It grew. Margins expanded. Free cash flow surged past $14 billion. The thing that changed is the multiple investors are willing to pay for 10–13% growth at a company of this size.
That distinction matters. If the business had actually broken, the selloff would be justified. If the business kept growing while the valuation reset into historically cheap territory, it's a different trade entirely. The evidence points to the latter.
What the market punished versus what actually happened
Salesforce's Q1 FY2027 results, reported May 27, showed revenue of $11.13 billion, up 13% year-over-year and ahead of Wall Street consensus. Non-GAAP operating margin jumped 250 basis points to 34.8%. That is not the profile of a company in structural decline. It's the profile of a business that is growing slower than its golden era while squeezing more operating leverage from every dollar of revenue.
The market didn't care. Shares sold off through the quarter anyway, extending the 30% year-to-date decline. The P/E multiple was cut roughly 34% during the drawdown, according to market data. Multiple compression of that magnitude on a company still growing 13% with expanding margins is not a business problem. It's a re-rating.
The AI story has receipts, not just slides
Salesforce has been pushing Agentforce - its AI agent platform - for two fiscal years now. The skepticism was warranted early on. The whole market was full of AI claims with no revenue to show. But Salesforce has actual numbers to stand on.
Agentforce crossed $1 billion in annual recurring revenue in Q1 FY2027. Combined AI and data ARR hit $3.4 billion. The company delivered 3.8 billion Agentic Work Units during the quarter - that's the usage metric that proves customers are actually running these agents in production, not sitting on pilot programs. Current remaining performance obligation - the value of contracted revenue not yet recognized - hit $35.1 billion, up 16% year-over-year. That backlog growth is the leading indicator, and it's still accelerating.
I don't buy AI narratives without revenue. Salesforce has the revenue.
Free cash flow and the $25 billion buyback cushion
Here's where the valuation math gets interesting for investors sitting on the sidelines.
Salesforce generated $14.4 billion in free cash flow during fiscal 2026, a 34.7% FCF margin on revenue. That cash machine is what funded a $25 billion share buyback announced in early 2026 - and there's still cash left over. For context, annual FCF grew from $9.5 billion in 2024 to $12.4 billion in 2025, then to $14.4 billion in fiscal 2026. Three years of compounding cash generation, even as the company invested heavily in AI infrastructure.
Free cash flow is the metric that matters most when growth slows. A company that can still generate $14 billion a year in cash while reinvesting in its next growth platform gives investors a floor that pure-growth stories don't have. The buyback provides share count reduction and EPS support even if the stock stays flat. That's real de-risking, not a theoretical comfort.
The valuation reset versus the business reality
This is the core of the trade. Salesforce's full-year FY2027 guidance sits at $45.9–$46.2 billion in revenue, implying roughly 11% growth. Adjusted EPS guidance is $14.06–$14.12. The stock trades around $171, down from levels above $240 earlier in the year. The consensus analyst price target sits at roughly $259 - implying 51% upside - though Citigroup just cut its target from $188 to $187 on May 28, reflecting lingering near-term caution.
At $171, the stock is pricing in a narrative where Salesforce becomes a slow-growth legacy software name. The actual business is a 13% growth rate with 35% operating margins, $14 billion in annual FCF, and an AI product line crossing $1 billion in ARR for the first time. That's not a legacy name. That's a cash-generating growth platform trading at a discount to its own current execution.
The growth has decelerated from its peak. I'm not denying that. Revenue growth was 20%+ in prior years. It's now in the 10–13% range. The multiple deserves to compress. The question is whether it has compressed too far, too fast. When a multiple drops 34% on a business that just grew 13% with expanding margins, the answer tends toward yes.
What could go wrong
Three risks keep this from being a reckless buy.
First, growth deceleration is real. If FY2027 full-year growth comes in at the low end of the 11% guidance range and cRPO growth slows materially, the story reverts to mature software and the multiple won't re-expand.
Second, AI monetization could plateau. Agentforce is real at $1 billion ARR, but that's still a fraction of the $46 billion revenue base. If agent adoption stalls or enterprises reduce AI budgets, the narrative engine stops.
Third, enterprise IT spending is cyclical. Salesforce's customers are large corporations, and corporate budget tightening would hit renewal rates, expansion deals, and deal velocity - all feeding back into that cRPO number.
The catalyst clock
Q2 FY2027 earnings, expected in late August, is the next test. Investors need to see cRPO growth holding above 12–14%, operating margins staying in the 34–35% range, and Agentforce ARR showing continued quarterly progression past the $1 billion mark. If those metrics hold, the multiple has work to do catching back up to the business.
Verdict: Buy
The competitor service is right about one thing: Salesforce is no longer the hyper-growth stock that justified its previous multiple. What they're wrong about is concluding the stock is a flop because the business stopped growing at 20%. A 13% growth rate, 34.8% operating margins, $14.4 billion in free cash flow, and an AI platform with $1 billion in ARR is not a flopping business. It's a company that is still executing while the market has already priced it like a disappointment.
The valuation reset is faster than the business deterioration. That's the trade. At $171, the stock gives investors room for the business to keep growing while the multiple works its way back toward where it should be for a company that generates $14 billion a year in cash. I'm buying into the slide.
Watch cRPO growth and Agentforce ARR at the next earnings print. If cRPO slips below 10% or Agentforce ARR stalls, the thesis breaks. Until then, the disconnect between price and performance is wide enough to act on.